Natco Pharma gains on launching additional strengths for generic version of Revlimid in USA
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Natco Pharma is currently trading at Rs. 564.70, up by 4.45 points or 0.79% from its previous closing of Rs. 560.25 on the BSE.
The scrip opened at Rs. 568.35 and has touched a high and low of Rs. 568.40 and Rs. 559.55 respectively. So far 586 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 872.60 on 10-Mar-2022 and a 52 week low of Rs. 502.00 on 02-Feb-2023.
Last one week high and low of the scrip stood at Rs. 580.00 and Rs. 556.20 respectively. The current market cap of the company is Rs. 10227.77 crore.
The promoters holding in the company stood at 48.82%, while Institutions and Non-Institutions held 26.65% and 24.53% respectively.
Natco Pharma has launched additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, through its marketing partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries.
With this launch the companies made available all the strengths of lenalidomide in the US market. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
